In the last decade, advances in the knowledge of the biology (deep understanding of the epidermal growth factor receptor, EGFR, gene mutations) and immunology (involvement of the immune system) of the tumor cells led to the development of EGFR tyrosine kinase inhibitors (TKIs) and of immune checkpoint inhibitors (ICIs). Here, EGFR is linked to neoplasm.